Breaking Down Metastatic Triple-Negative Breast Cancer Treatments
Season 7, Episode 2, Dec 31, 2025, 05:00 PM
Share
Subscribe
CURE spoke with Dr. Natalie S. Berger to discuss treatment advancements for patients with metastatic triple-negative breast cancer.
CURE sat down with Dr. Natalie S. Berger for the latest episode of the “Cancer Horizons” podcast to discuss frontline treatment options for patients with metastatic triple-negative breast cancer. Berger, who recently spoke at CURE’s Educated Patient® Metastatic Breast Cancer Summit, is an assistant professor of medicine at Columbia University Irving Medical Center Division of Hematology and Medical Oncology and the associate director of breast medical oncology at New York Presbyterian-Hudson Valley Hospital in New York.
Key points discussed by Berger in the podcast included the importance of personalized medicine, with treatments tailored to tumor and patient characteristics. Immunotherapy, particularly Keytruda (pembrolizumab), is often used, especially for PDL-1 positive patients. PARP inhibitors are recommended for BRCA mutation-positive patients. Antibody-drug conjugates, like Trodelvy (sacituzumab govitecan), are emerging as effective treatments, shown to be superior to chemotherapy in combination with immunotherapy.
Additionally, patients are encouraged to be active in their treatment decisions, engage in exercise and proper nutrition, and consider enrolling in clinical trials, while caregivers are advised to support patients by understanding their needs and providing appropriate assistance.
Key points discussed by Berger in the podcast included the importance of personalized medicine, with treatments tailored to tumor and patient characteristics. Immunotherapy, particularly Keytruda (pembrolizumab), is often used, especially for PDL-1 positive patients. PARP inhibitors are recommended for BRCA mutation-positive patients. Antibody-drug conjugates, like Trodelvy (sacituzumab govitecan), are emerging as effective treatments, shown to be superior to chemotherapy in combination with immunotherapy.
Additionally, patients are encouraged to be active in their treatment decisions, engage in exercise and proper nutrition, and consider enrolling in clinical trials, while caregivers are advised to support patients by understanding their needs and providing appropriate assistance.